We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.36 | -0.28% | 128.44 | 129.76 | 127.985 | 129.76 | 7,441,700 | 22:02:26 |
From May 2019 to May 2024
By Chelsey Dulaney
Gilead Sciences Inc. has agreed to buy privately-held EpiTherapeutics ApS for $65 million, giving the drug maker a foothold into the field of epigenetics.
Epigenetics is the study of how environmental influences alter whether particular genes are activated.
Denmark-based EpiTherapeutics develops cancer treatments, focusing on the enzymes involved in the regulation of transcription in cancer.
Gilead, meanwhile, has two key hepatitis C drugs, Sovaldi and Harvoni, which generated about $4.45 billion in sales in the first quarter of the year.
The drugs represent two of the most successful drug launches ever, marked by their high cure rates, fewer side effects and imposing price tags. But they also face increasing competition from new hepatitis C treatments like AbbVie Inc.'s Viekira Pak, which started sales in December. Merck & Co. has a hepatitis C treatment in the works.
Write to Chelsey Dulaney at Chelsey.Dulaney@wsj.com
Access Investor Kit for Gilead Sciences, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US3755581036
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
